Insulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions

Reuters

06-19

Insulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions

Insulet Corporation has announced its participation in the upcoming American Diabetes Association $(ADA.AU)$ 85th Scientific Sessions scheduled from June 20 to 23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. During the event, Insulet plans to share detailed insights from its groundbreaking SECURE-T2D and RADIANT trials, focusing on the impact of Omnipod® 5 on improved health outcomes for people with diabetes. The company will present real-world glycemic outcomes data from over 23,000 individuals with type 2 diabetes in the United States using Omnipod 5. Additionally, Insulet will engage attendees with booth activities, including podcasts, hands-on demonstrations, and immersive experiences. Results from these trials were previously presented at last year's ADA conference, with further insights set to be disclosed at this year's sessions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250619043429) on June 19, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544168071"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544168071\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2544168071?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-19 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544168071","market":"nz","top_or_hot":-1,"title":"Insulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Insulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Insulet Corporation has announced its participation in the upcoming American Diabetes Association <a href=\"https://laohu8.com/S/ADA.AU\">$(ADA.AU)$</a> 85th Scientific Sessions scheduled from June 20 to 23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. During the event, Insulet plans to share detailed insights from its groundbreaking SECURE-T2D and RADIANT trials, focusing on the impact of Omnipod® 5 on improved health outcomes for people with diabetes. The company will present real-world glycemic outcomes data from over 23,000 individuals with type 2 diabetes in the United States using Omnipod 5. Additionally, Insulet will engage attendees with booth activities, including podcasts, hands-on demonstrations, and immersive experiences. Results from these trials were previously presented at last year's ADA conference, with further insights set to be disclosed at this year's sessions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250619043429) on June 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-19 18:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Insulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Insulet Corporation has announced its participation in the upcoming American Diabetes Association <a href=\"https://laohu8.com/S/ADA.AU\">$(ADA.AU)$</a> 85th Scientific Sessions scheduled from June 20 to 23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. During the event, Insulet plans to share detailed insights from its groundbreaking SECURE-T2D and RADIANT trials, focusing on the impact of Omnipod® 5 on improved health outcomes for people with diabetes. The company will present real-world glycemic outcomes data from over 23,000 individuals with type 2 diabetes in the United States using Omnipod 5. Additionally, Insulet will engage attendees with booth activities, including podcasts, hands-on demonstrations, and immersive experiences. Results from these trials were previously presented at last year's ADA conference, with further insights set to be disclosed at this year's sessions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250619043429) on June 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065170008.USD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250619:nNDL6ytM94:1","article_id":"2544168071","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544168071","pubTimestamp":1750327224,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Insulet Corporation has announced its participation in the upcoming American Diabetes Association  85th Scientific Sessions scheduled from June 20 to 23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. During the event, Insulet plans to share detailed insights from its groundbreaking SECURE-T2D and RADIANT trials, focusing on the impact of Omnipod 5 on improved health outcomes for people with diabetes. The company will present real-world glycemic outcomes data from over 23,000 individuals with type 2 diabetes in the United States using Omnipod 5. Additionally, Insulet will engage attendees with booth activities, including podcasts, hands-on demonstrations, and immersive experiences. Results from these trials were previously presented at last year's ADA conference, with further insights set to be disclosed at this year's sessions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide ac","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4588":"碎股","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4082":"医疗保健设备","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","PODD":"银休特","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","BK4551":"寇图资本持仓","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","BK4566":"资本集团"},"translate_title":"Insulet Corporation在ADA科学会议上公布突破性试验结果和新的Omnipod 5见解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PODD":0.9},"content_text":"Insulet Corporation Unveils Groundbreaking Trial Results and New Omnipod 5 Insights at ADA Scientific Sessions\n    \n\n        Insulet Corporation has announced its participation in the upcoming American Diabetes Association $(ADA.AU)$ 85th Scientific Sessions scheduled from June 20 to 23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. During the event, Insulet plans to share detailed insights from its groundbreaking SECURE-T2D and RADIANT trials, focusing on the impact of Omnipod® 5 on improved health outcomes for people with diabetes. The company will present real-world glycemic outcomes data from over 23,000 individuals with type 2 diabetes in the United States using Omnipod 5. Additionally, Insulet will engage attendees with booth activities, including podcasts, hands-on demonstrations, and immersive experiences. Results from these trials were previously presented at last year's ADA conference, with further insights set to be disclosed at this year's sessions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250619043429) on June 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}